Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to Fulcrum Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. As a reminder, this conference is being recorded.
Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Greetings, and welcome to Fulcrum Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. As a reminder, this conference is being recorded.
Eight of 9 secondary end points were significantly improved with sotatercept versus placebo.
/PRNewswire/ -- Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel...
French CAR-T biotech Mnemo Therapeutics shutters its U.S. operations; Merck’s experimental heart drug sotatercept boosts exercise capacity in hypertension patients.
Sotatercept demonstrated statistically significant improvements in 8 of 9 secondary measures, including reduction in risk of clinical worsening or deathResults presented today at ACC.23/WCC and published in The New England Journal of MedicineRAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD o...